Aura Biosciences (AURA) Competitors $8.23 +0.05 (+0.61%) (As of 12/24/2024 01:47 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends AURA vs. EVO, KNSA, PRAX, RCUS, IMCR, NRIX, OCUL, TVTX, DAWN, and ARVNShould you be buying Aura Biosciences stock or one of its competitors? The main competitors of Aura Biosciences include Evotec (EVO), Kiniksa Pharmaceuticals (KNSA), Praxis Precision Medicines (PRAX), Arcus Biosciences (RCUS), Immunocore (IMCR), Nurix Therapeutics (NRIX), Ocular Therapeutix (OCUL), Travere Therapeutics (TVTX), Day One Biopharmaceuticals (DAWN), and Arvinas (ARVN). These companies are all part of the "pharmaceutical products" industry. Aura Biosciences vs. Evotec Kiniksa Pharmaceuticals Praxis Precision Medicines Arcus Biosciences Immunocore Nurix Therapeutics Ocular Therapeutix Travere Therapeutics Day One Biopharmaceuticals Arvinas Evotec (NASDAQ:EVO) and Aura Biosciences (NASDAQ:AURA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, community ranking, institutional ownership, analyst recommendations, profitability and media sentiment. Which has preferable valuation and earnings, EVO or AURA? Aura Biosciences has lower revenue, but higher earnings than Evotec. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvotec$777.05M2.28-$90.82MN/AN/AAura BiosciencesN/AN/A-$76.41M-$1.73-4.76 Does the media refer more to EVO or AURA? In the previous week, Aura Biosciences had 2 more articles in the media than Evotec. MarketBeat recorded 3 mentions for Aura Biosciences and 1 mentions for Evotec. Aura Biosciences' average media sentiment score of 1.29 beat Evotec's score of 0.55 indicating that Aura Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evotec 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aura Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend EVO or AURA? Evotec presently has a consensus target price of $5.93, indicating a potential upside of 18.67%. Aura Biosciences has a consensus target price of $23.00, indicating a potential upside of 179.47%. Given Aura Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Aura Biosciences is more favorable than Evotec.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evotec 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20Aura Biosciences 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29 Do institutionals and insiders hold more shares of EVO or AURA? 5.8% of Evotec shares are held by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are held by institutional investors. 1.0% of Evotec shares are held by company insiders. Comparatively, 5.4% of Aura Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is EVO or AURA more profitable? Evotec's return on equity of 0.00% beat Aura Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets EvotecN/A N/A N/A Aura Biosciences N/A -41.57%-36.43% Does the MarketBeat Community favor EVO or AURA? Aura Biosciences received 17 more outperform votes than Evotec when rated by MarketBeat users. Likewise, 62.16% of users gave Aura Biosciences an outperform vote while only 54.55% of users gave Evotec an outperform vote. CompanyUnderperformOutperformEvotecOutperform Votes654.55% Underperform Votes545.45% Aura BiosciencesOutperform Votes2362.16% Underperform Votes1437.84% Which has more risk & volatility, EVO or AURA? Evotec has a beta of 1.44, indicating that its stock price is 44% more volatile than the S&P 500. Comparatively, Aura Biosciences has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500. SummaryAura Biosciences beats Evotec on 11 of the 15 factors compared between the two stocks. Ad Behind the Markets$19 for a FULL YEAR of stock picks?!We're offering you the chance to subscribe to Behind the Markets for an ENTIRE YEAR for just $19. But why? Because there is a very small window of time... as little as 25 days from now... That will change the market forever.Click here to get in now>>> Get Aura Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AURA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AURA vs. The Competition Export to ExcelMetricAura BiosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$411.10M$2.96B$5.23B$9.28BDividend YieldN/A1.91%5.12%4.28%P/E Ratio-4.7646.4687.6917.27Price / SalesN/A420.871,168.45119.91Price / CashN/A174.7643.2337.82Price / Book1.803.924.834.94Net Income-$76.41M-$42.00M$120.76M$225.76M7 Day Performance1.48%2.90%2.49%3.92%1 Month Performance-8.15%-1.69%17.55%1.71%1 Year Performance-8.45%15.34%28.51%15.79% Aura Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AURAAura Biosciences2.5289 of 5 stars$8.23+0.6%$23.00+179.5%-5.6%$411.10MN/A-4.7650Positive NewsEVOEvotec1.3556 of 5 stars$4.45-0.4%$5.93+33.3%-56.8%$1.58B$777.05M0.005,061KNSAKiniksa Pharmaceuticals2.6334 of 5 stars$20.35-1.2%$36.60+79.9%+9.3%$1.47B$384.10M-145.35220Positive NewsPRAXPraxis Precision Medicines2.0705 of 5 stars$77.04+0.7%$146.33+89.9%+279.4%$1.44B$1.61M-7.48110RCUSArcus Biosciences2.8683 of 5 stars$15.69+1.2%$34.00+116.7%-12.3%$1.44B$263M-4.98500IMCRImmunocore2.5133 of 5 stars$28.23-0.4%$65.64+132.5%-56.3%$1.41B$296.31M-29.72497NRIXNurix Therapeutics2.584 of 5 stars$19.82-0.1%$30.35+53.1%+104.5%$1.40B$56.42M-6.81300OCULOcular Therapeutix3.7029 of 5 stars$8.56+0.7%$16.71+95.3%+101.2%$1.35B$61.44M-6.48267TVTXTravere Therapeutics2.6744 of 5 stars$17.12-0.3%$23.67+38.2%+89.1%$1.34B$203.45M-3.76460Positive NewsDAWNDay One Biopharmaceuticals1.6228 of 5 stars$12.62-1.3%$35.71+183.0%-15.7%$1.27B$101.95M-12.2560Positive NewsARVNArvinas2.1053 of 5 stars$18.09-2.1%$63.50+251.0%-52.7%$1.24B$161.10M-3.87445 Related Companies and Tools Related Companies Evotec Competitors Kiniksa Pharmaceuticals Competitors Praxis Precision Medicines Competitors Arcus Biosciences Competitors Immunocore Competitors Nurix Therapeutics Competitors Ocular Therapeutix Competitors Travere Therapeutics Competitors Day One Biopharmaceuticals Competitors Arvinas Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AURA) was last updated on 12/26/2024 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon Musk could help pay for your retirementElon Musk is the richest man in the world... And he's pouring trillions into a unique investment.Brownstone Research | SponsoredTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aura Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aura Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
